Chroman ER Degraders With Oral Bioavailability and Near-Complete ERα Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for ER+ breast cancer, such as fulvestrant, achieve only partial degradation of estrogen receptors (ERα) and have limitations due to poor solubility and lack of oral bioavailability, necessitating the development of new compounds that can induce nearly complete degradation of ER protein.
Innovation Solution
Development of chroman derivatives that act as estrogen receptor degraders, utilizing ubiquitin-mediated degradation pathways to target ERα for proteasome-dependent degradation, offering a new class of therapeutics for treating ER+ metastatic breast cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fulvestrant is used to degrade ER protein, then ER degradation is achieved, but oral bioavailability is poor and solubility is limited
Solution Approach 1:
The patent modifies the chemical structure of fulvestrant by changing key parameters (molecular weight, functional groups, and spatial arrangement) to create chroman derivatives with improved pharmacokinetic properties while maintaining ER degradation efficacy
Solution Approach 2:
The invention creates composite molecular structures by combining chroman core with specific side chains and functional groups to achieve both ER binding affinity and improved oral bioavailability
2Reliability
If fulvestrant is used to degrade ER protein, then ER degradation is achieved, but solubility is poor
Solution Approach 1:
The patent introduces polar functional groups and modifies molecular parameters in the chroman derivative structure to enhance solubility while preserving the ability to bind and degrade ER protein
3Reliability
If existing SERDs are used, then partial ER degradation is achieved, but complete degradation is not realized
Solution Approach 1:
The chroman derivatives act as intermediaries that facilitate the ubiquitin-proteasome system to recognize and degrade ER protein, enabling complete degradation by properly positioning the ER protein for proteasomal processing
Solution Approach 2:
The invention modifies the molecular parameters of SERDs to enhance their ability to induce ER degradation, achieving complete degradation by optimizing binding affinity and degradation pathway engagement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chroman derivatives provide nearly complete degradation of ER protein, potentially enhancing treatment efficacy for ER+ breast cancer by leveraging natural cellular mechanisms.
Implementation Method 1
utilizing ubiquitin-mediated degradation pathways to target ERα for proteasome-dependent degradation
Implementation Method 2
target ERα for proteasome-dependent degradation
Data Source
AI summary
Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).